Location：
Home >
EneSoothe® MIX-KAVA
  • EneSoothe® MIX-KAVA
    • 1/1
  • EneSoothe® MIX-KAVA

EneSoothe® MIX-KAVA

INCI Name Piper Methysticum Root Extract, Opuntia Streptacantha Leaf Extract, Butylene Glycol, Pentylene Glycol
Application Soothing and Anti-inflammation
Recommended use level 0.5~5.0%
Product Overview

EneSoothe® MIX-KAVA is a botanical neuro-soothing active inspired by the calming properties of Kava. By supporting GABA-mediated skin calming pathways, it helps regulate sensory discomfort, reduce skin sensitivity, and restore long-lasting comfort for sensitive skin.

Plant Source

Across the islands of the South Pacific, Piper methysticum (Kava) has been cherished for centuries as more than a botanical—it is a symbol of welcome, harmony, and relaxation. In Vanuatu, the birthplace of kava culture, sharing a bowl of kava is a time-honored tradition that helps calm the body and mind after physical or emotional stress.

Inspired by this unique botanical heritage, EneSoothe® MIX-KAVA brings the calming philosophy of Kava into modern skincare. Rich in naturally occurring kavalactones, Kava helps support GABA-mediated neuro-sensory pathways to promote skin comfort and relieve sensations of burning, stinging, and itching associated with sensitive skin. Opuntia streptacantha complements the formula with soothing, antioxidant, and skin-repairing properties, helping restore comfort and resilience to stressed skin.

Key Benefits

• Supports GABA-mediated neuro-sensory calming pathways

• Helps reduce skin sensitivity and discomfort • Helps relieve burning, stinging, itching, and irritation sensations • Helps calm inflammatory responses and visible redness • Supports skin tolerance and comfort for sensitive skin

Efficacy Data

In vitro

In vivo

Neuro-Sensory Regulation

  • 44% increase in GABA-A receptor expression at 0.1%

  • 28.87% reduction in TRPV1 expression at 0.0625%

  • 28.2% reduction in intracellular Na⁺ level at 0.1%


Anti-Inflammatory Activity

  • 27.29% reduction in nitric oxide (NO) production at 500 μg/mL

  • 75.46% inhibition of 5-LOX activity at 2%

  • 30.03% reduction in lactic acid-induced stinging score after 28 days of use (0.3%)

  • 23.35% reduction in facial redness after 28 days of use (0.3%)

  • 100% of participants reported reduced burning, stinging, itching, dryness, and redness (0.3%)